CompletedNot Applicable

Development and Multicenter Validation of a Novel Bio-Anatomical Staging System for Predicting Survival and Tailoring Adjuvant Therapy in ESCC After Neoadjuvant Chemoimmunotherapy.

China414 participantsStarted 2025-09-01

Plain-language summary

The goal of this retrospective observational study is to build and validate a "bio-anatomical" prognostic model for patients with esophageal squamous cell carcinoma (ESCC) who underwent neoadjuvant immunochemotherapy (nICT) followed by radical surgery. The main question it aims to answer is: Can a "bio-anatomical" prognostic nomogram accurately predict overall survival and help guide individualized post-surgery treatment for ESCC patients after nICT better than traditional staging? Researchers will retrospectively analyze the clinical, pathological (including a new lymph node response indicator), and overall survival data of 414 eligible patients treated across three medical centers between 2019 and 2025.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age between 18 and 80 years. * Histologically confirmed esophageal squamous cell carcinoma (ESCC). * Received at least one cycle of neoadjuvant immunochemotherapy (nICT) preoperatively. * Underwent subsequent radical esophagectomy. Exclusion Criteria: * Previous history of other malignant tumors. * Received other preoperative anti-tumor treatments (such as radiotherapy) besides nICT. * Incomplete clinicopathological or follow-up data. * Perioperative death.

What they're measuring

Overall Survival (OS)

Timeframe: From date of diagnosis until the date of death from any cause, assessed up to 120 months.

Trial details

NCT IDNCT07488624

SponsorSichuan University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-01

View on ClinicalTrials.gov More ESCC trials